Twitter:

$MTNB MAT9001 top-line results meet primary and secondary endpts in 1st human trial
vs. Vascepa [link] #dyslipidemia
MAT9001 shows superiority vs. Vascepa on bioavailability, #triglyceride #reductions &
other lipid endpts[link] $MTNB
$MTNB MAT9001 is the first orally taken #dyslipidemia product reported to significantly
reduce #PCSK9:[link]
Click to learn about $MTNB MAT9001 1st human trial vs. Vascepa:[link] #dyslipidemia
Statistically significant reduction of PCSK9 show MAT9001 ability to meet unmet need:
[link] $MTNB #dyslipidemia
Facebook.Google+/Linkedin
Matinas drug candidate MAT9001 meets Primary and Secondary Endpoint in head-tohead comparative study vs. Vascepa and showed superiority on biodiversity, triglyceride
reduction and other lipid endpoints. These statistically significant results support the
premise that the purposeful design of our MAT9001 omega-3 fatty acid composition and
delivery system has the potential to be a best-in-class product for the treatment of
dyslipidemia, said CEO Roelof Rongen. [link]